Europe Veterinary Healthcare Market Introduction and Overview
According to SPER Market Research, the Europe Veterinary Healthcare Market is estimated to reach USD 21.62 billion by 2033 with a CAGR of 7.8%.
The report includes an in-depth analysis of the Europe Veterinary Healthcare Market, including market size and trends, product mix, distribution channels, and supplier analysis. The term "veterinary healthcare" describes the medical attention and services given to animals, especially domestic pets and livestock, with the goal of ensuring their health and welfare. It covers a broad spectrum of procedures and therapies meant to avoid, identify, and manage diseases, wounds, and other medical issues in animals. Through routine vaccinations, parasite control, dental care, nutrition counseling, and wellness check-ups, it involves steps to prevent illnesses and maintain the general health of animals. Additionally, by addressing animal abuse or neglect, advocating for humane treatment, and guaranteeing the wellbeing of animals in various settings, veterinary healthcare professionals also play a critical role in promoting animal welfare.
- VolitionRx launched its Nu. Q Vet Cancer Screening Test in the United States and Europe in November 2022, using Heska's veterinary diagnostic laboratories as its global supply partner.
- The Livestock Vaccination Guideline was launched in May 2022 by the United Kingdom National Office of Animal Health (NOAH) to assist veterinarians and farmers in improving the health and welfare of sheep and cattle in the United Kingdom, as well as to support farm resilience and sustainable productivity improvements.
Market Opportunities and Challenges
Opportunities: The primary factor driving the European veterinary healthcare market is rising animal adoption in European countries, combined with increased government initiatives and improved animal healthcare. According to the Pet Food Manufacturers Association, 3.2 million UK households had acquired a pet since the pandemic began in 2021. The UK has 34 million pets, which include 12 million cats, 12 million dogs, 3.2 million small mammals such as guinea pigs and hamsters, 3 million birds, and 1.5 million reptiles. Furthermore, technological advancements in animal diagnostic technologies for accurate diagnostics, as well as increased penetration by some of the market's key and dominant players, are expected to drive market growth.
Challenges: Numerous issues affect the dynamics and general efficacy of the European veterinary healthcare market. The rising incidence of zoonotic illnesses, or infections spread from animals to humans, is one major problem. This calls for sophisticated and specialized care, placing pressure on veterinary healthcare systems to keep up with new illnesses and implement efficient preventative measures. Financial difficulties are also faced by pet owners and healthcare professionals due to the rising expense of veterinary care and the growing demand for pet insurance. Moreover, differences in standards, licensing, and approval procedures for veterinary medications and therapies are a result of regulatory complexities among European nations, which impedes the smooth integration of markets. The market's fragmented structure, which includes a large number of small and medium-sized businesses, presents additional difficulties for effective distribution networks and streamlined operations.
Market Competitive Landscape
The existence of multiple companies operating both globally and regionally has resulted in fragmentation within the European veterinary healthcare market. Among the well-known and market-share-holding companies analyzed in the competitive landscape are Abaxis Inc., Bayer AG, Benfield Pet Hospital, Boehringer Ingelheim International GmbH, Ceva Animal Health Inc., CVS Group, ECO Animal Health, Elanco, Greencross Vets, Idexx Laboratories, MSD Animal Health, The Bergh Memorial Animal Hospital, Vetoquinol UK Limited, Virbac, and Zoetis Animal Healthcare.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Product, By Animal Type
|
| Regions covered | Germany, United Kingdom, France, Italy, Spain, Rest of Europe
|
| Companies Covered | Boehringer Ingelheim International GmbH, Ceva Sante Animale (CEVA), Dechra Pharmaceuticals PLC., Dopharma, ECO Animal Health Group Plc, Elanco, Hipra, Idexx Laboratories, Inc., Laboratorios Syva, MSD Animal Health, Norbrook, Orion Corporation, Vetoquinol S.A., Virbac, Others.
|
COVID-19 Impact on Europe Veterinary Healthcare Market
The European pandemic caused supply chain disruptions and delays in the delivery of diagnostic equipment, consumables, and reagents, which initially had a negative effect on the market during COVID-19. The market faced a number of major challenges during a pandemic, such as port checkpoints and truck traffic jams that slowed down the delivery of essential supplies; several nations imposed export bans; and only a small number of manufacturing facilities were operational. Consequently, at first, these factors hindered the market's growth rate. Conversely, the pandemic's outbreak led to a rise in pet ownership in Spain, which helped the market expand.
Key Target Audience:
- Veterinarians and Veterinary Practitioners
- Pet Owners and Animal Enthusiasts
- Animal Farm Owners and Livestock Producers
- Pharmaceutical and Biotechnology Companies
- Retailers and Distributors
Our in-depth analysis of the Europe Veterinary Healthcare Market includes the following segments:
|
By Product: |
Therapeutics
Diagnostics
|
|
By Animal Type: |
Dogs and Cats
Horses
Ruminants
Swine
Poultry
Others
|
|
By Region: |
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
|
Key Topics Covered in the Report:
- Europe Veterinary Healthcare Market Size (FY’2023-FY’2033)
- Overview of Europe Veterinary Healthcare Market
- Segmentation of Europe Veterinary Healthcare Market By Product (Therapeutics, Diagnostics)
- Segmentation of Europe Veterinary Healthcare Market By Animal Type (Dogs and Cats, Horses, Ruminants, Swine, Poultry, Others)
- Expansion Analysis of Europe Veterinary Healthcare Market
- Problems and Obstacles in Europe Veterinary Healthcare Market
- Competitive Landscape in the Europe Veterinary Healthcare Market
- Impact of COVID-19 and Demonetization on Europe Veterinary Healthcare Market
- Details on Current Investment in Europe Veterinary Healthcare Market
- Competitive Analysis of Europe Veterinary Healthcare Market
- Prominent Players in the Europe Veterinary Healthcare Market
- SWOT Analysis of Europe Veterinary Healthcare Market
- Europe Veterinary Healthcare Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Europe Veterinary Healthcare Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Europe Veterinary Healthcare Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Europe Veterinary Healthcare Market
7. Europe Veterinary Healthcare Market, By Product (USD Million)
7.1. Europe Veterinary Healthcare Market Value Share and Forecast, By Product, 2023-2033
7.2. Therapeutics
7.2.1. Vaccines
7.2.2. Parasiticides
7.2.3. Anti-infectives
7.2.4. Medical Feed Additives
7.2.5. Others
7.3. Diagnostics
7.3.1. Immunodiagnostic Tests
7.3.2. Molecular Diagnostics
7.3.3. Diagnostic Imaging
7.3.4. Clinical Chemistry
7.3.5. Others
8. Europe Veterinary Healthcare Market, By Animal Type (USD Million)
8.1. Europe Veterinary Healthcare Market Value Share and Forecast, By Animal Type, 2023-2033
8.2. Dogs and Cats
8.3. Horses
8.4. Ruminants
8.5. Swine
8.6. Poultry
8.7. Others
9. Europe Veterinary Healthcare Market Forecast, 2019-2033 (USD Million)
9.1. Europe Veterinary Healthcare Market Size and Market Share
10. Europe Veterinary Healthcare Market, By Product, 2019-2033 (USD Million)
10.1. Europe Veterinary Healthcare Market Size and Market Share By Product (2019-2026)
10.2. Europe Veterinary Healthcare Market Size and Market Share By Product (2027-2033)
11. Europe Veterinary Healthcare Market, By Animal Type, 2019-2033 (USD Million)
11.1. Europe Veterinary Healthcare Market Size and Market Share By Animal Type, (2019-2026)
11.2. Europe Veterinary Healthcare Market Size and Market Share By Animal Type, (2027-2033)
12. Europe Veterinary Healthcare Market, By Region, 2019-2033 (USD Million)
12.1. Europe Veterinary Healthcare Market Size and Market Share By Region (2019-2026)
12.2. Europe Veterinary Healthcare Market Size and Market Share By Region (2027-2033)
12.3. Germany
12.4. United Kingdom
12.5. France
12.6. Italy
12.7. Spain
12.8. Rest of Europe
13. Company Profile
13.1. Boehringer Ingelheim International GmbH
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. Ceva Sante Animale (CEVA)
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Dechra Pharmaceuticals PLC.
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Dopharma
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. ECO Animal Health Group Plc
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. Elanco
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Hipra
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Idexx Laboratories, Inc.
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Laboratorios Syva
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. MSD Animal Health
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Norbrook
13.11.1. Company details
13.11.2. Financial outlook
13.11.3. Product summary
13.11.4. Recent developments
13.12. Orion Corporation
13.12.1. Company details
13.12.2. Financial outlook
13.12.3. Product summary
13.12.4. Recent developments
13.13. Vetoquinol S.A.
13.13.1. Company details
13.13.2. Financial outlook
13.13.3. Product summary
13.13.4. Recent developments
13.14. Virbac
13.14.1. Company details
13.14.2. Financial outlook
13.14.3. Product summary
13.14.4. Recent developments
13.15. Others
14. Reference Links
15. Conclusion
16. Research Scope